The company has developed a drug discovery platform that combines functional fragment screening with X-ray crystallography co-crystallization to design and synthesize New Chemical Entities (NCEs) with drug-like properties. Their focus is on diseases caused by protein misfolding, particularly neurodegenerative disorders. Plex Pharmaceuticals aims to accelerate academic discoveries into safe and effective treatments for unmet medical needs, with a specific focus on treating ALS.